To further evaluate the combination effect of PARP inhibitor and AKT inhibitor, five ovarian cancer cell lines (OVCA433, OVCAR8, A2780, SKOV3, and HEY) were studied. The gene discussed is PARP1; the disease is ovarian cancer.